Magnetic Resonance Imaging of the Lung: Oncological Applications

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07486219

Enrollment

Registered

2026-03-20

Start date

2020-01-15

Completion date

2026-04-01

Last updated

2026-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer (NSCLC)

Brief summary

Lung neoplasms are characterized by a complex interaction between tumor cells and a variety of resident and infiltrating host elements, secreted factors, and extracellular matrix proteins, collectively referred to as the microenvironment. Nowadays, in the setting of lung cancer, and in particular non-small cell lung cancer (NSCLC), the evaluation of microenvironment characteristics can only be performed by a pathologist and only on histological material. By combining different MRI parameters, it may be possible to create a specific imaging "signature" for the three different immune phenotypes and thus be able to make a distinction based on MRI examination.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Primary NSCLC of the lung (TNM 8th edition T parameter ≥T1c) * Biopsy examination of the primary tumor adequate at least for PDL-1 quantification * Staging CT scan with uncertain N parameter and definite M parameter.

Exclusion criteria

* Absolute contraindications to magnetic resonance imaging or the administration of gadolinium-based contrast agents

Design outcomes

Primary

Measure	Time frame
assessment of the ability of advanced magnetic resonance imaging techniques to distinguish between immune phenotypes in NSCLC.	up to 36 months

Countries

Italy

Contacts

CONTACTChandra Bortolotto

c.bortolotto@smatteo.pv.it+390382503761

Outcome results